Evolus, Inc.: insider trades · United States · SEC (Form 4)

About Evolus, Inc.

Evolus, Inc. (NASDAQ: EOLS) is a U.S.-listed aesthetics company traded on the NASDAQ market in the United States (United States). Headquartered in Newport Beach, California, the company focuses on the cash-pay medical aesthetics segment, where patients typically pay out of pocket and providers compete on brand, convenience, clinical performance, and patient engagement. Evolus positions itself as a “performance beauty” company, combining differentiated injectable products with a digital, customer-centric commercial model. ([investors.evolus.com](https://investors.evolus.com/overview/default.aspx)) The company’s foundation rests on Jeuveau® (prabotulinumtoxinA-xvfs), a botulinum toxin type A product approved by the FDA in 2019 for the temporary improvement of moderate to severe glabellar lines. Outside the United States, the same product is marketed as Nuceiva®. Evolus has since expanded beyond neurotoxin into hyaluronic acid fillers with Evolysse®, a next-generation injectable HA gel collection launched in the U.S. in 2025; internationally, that line is branded as Estyme®. These products target core aesthetic use cases such as facial lines, contouring, and volume restoration. ([investors.evolus.com](https://investors.evolus.com/overview/default.aspx)) From a competitive standpoint, Evolus operates in a crowded market dominated by large global aesthetics and pharmaceutical players. Its investment case depends on sustained share gains, brand relevance, repeat usage, and the successful rollout of a broader multi-product portfolio. The company highlights its Evolus Rewards™ loyalty platform as a key commercial differentiator, supporting patient retention and physician engagement. Management also states that Jeuveau has reached about 14% U.S. market share, which underscores meaningful traction for a relatively focused player in the neurotoxin category. ([investors.evolus.com](https://investors.evolus.com/overview/default.aspx)) Geographically, Evolus is still anchored in the U.S. but is clearly building an international footprint. Its product portfolio is sold across multiple markets, including the United States, Canada, Europe, and Australia, with further expansion underway. In 2026, the company announced the commercial launch of Estyme injectable HA gels in Europe and outlined plans for additional U.S. and international milestones. This makes Evolus more than a one-product story: it is evolving into a broader aesthetics platform with cross-border growth potential. ([investors.evolus.com](https://investors.evolus.com/press-releases-and-news/news-details/2026/Evolus-Reports-First-Quarter-2026-Financial-Results-Company-Delivers-Second-Consecutive-Quarter-of-Positive-Adjusted-EBITDA-and-Reaffirms-Full-Year-Outlook/default.aspx)) Recent operating updates have been constructive. In its first-quarter 2026 results, Evolus reported $73.1 million in revenue, 7% year-over-year growth, and a second consecutive quarter of positive Adjusted EBITDA. Management also reaffirmed full-year 2026 guidance for revenue of $327 million to $337 million and continued to point to margin improvement and operating leverage. For investors, the key takeaway is that Evolus is transitioning from a single-brand growth story toward a more diversified aesthetics franchise, while still facing the execution and competitive risks typical of a consumer-driven, cash-pay healthcare business. ([investors.evolus.com](https://investors.evolus.com/press-releases-and-news/news-details/2026/Evolus-Reports-First-Quarter-2026-Financial-Results-Company-Delivers-Second-Consecutive-Quarter-of-Positive-Adjusted-EBITDA-and-Reaffirms-Full-Year-Outlook/default.aspx))